Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REIMAGINE 1: CagriSema in Type 2 Diabetes on Diet and Exercise
2022-502677-42-00Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Apr 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of cagrilintide and semaglutide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Novo Nordisk. Primary endpoint: Change in HbA1c from baseline to end of treatment. Started Apr 2024; status: completed.
02
Drugs
cagrilintidesemaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2022-502677-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502677-42-00.